Nexalin Technology (NXL) said Monday it secured a patent for its deep intracranial frequency stimulation technology in treating substance use disorders.
The firm said the US Patent and Trademark Office granted its patent "Alternating Current Dynamic Frequency Stimulation Method for Opioid Use Disorder and Substance Use Disorder."
The technology may help regulate neural pathways linked to addiction and withdrawal symptoms, offering an alternative treatment pathway, Nexalin said.
Price: 1.97, Change: +0.08, Percent Change: +4.23
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments